Assembly Biosciences (NASDAQ:ASMB) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Other equities research analysts also recently issued research reports about the company. B. Riley assumed coverage on Assembly Biosciences in a research report on Friday. They set a “neutral” rating and a $35.00 price objective on the stock. ValuEngine downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. Finally, Jefferies Group assumed coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Assembly Biosciences currently has an average rating of “Hold” and a consensus price target of $39.25.

Shares of Assembly Biosciences (ASMB) traded down $1.79 during mid-day trading on Friday, reaching $43.12. The company had a trading volume of 131,196 shares, compared to its average volume of 113,888. Assembly Biosciences has a 12 month low of $12.15 and a 12 month high of $52.37. The company has a market capitalization of $904.07, a P/E ratio of -14.52 and a beta of 0.91.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total value of $29,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 4,000 shares of company stock valued at $157,660. 19.60% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors purchased a new stake in Assembly Biosciences in the second quarter valued at about $161,000. Parametric Portfolio Associates LLC raised its stake in Assembly Biosciences by 13.6% in the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 1,203 shares during the last quarter. Legal & General Group Plc purchased a new stake in Assembly Biosciences in the second quarter valued at about $212,000. Wells Fargo & Company MN purchased a new stake in Assembly Biosciences in the second quarter valued at about $213,000. Finally, State of Wisconsin Investment Board purchased a new stake in Assembly Biosciences in the second quarter valued at about $227,000. Institutional investors own 62.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Assembly Biosciences (ASMB) Lowered to Hold at BidaskClub” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/assembly-biosciences-asmb-lowered-to-hold-at-bidaskclub/1797625.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.